Sponsored Content
Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.
China Investments and Licensing DealsChina Investments and Licensing Deals
BPI Contributor
June 6, 2019
20 Min View
WuXi Vaccines has been formed to support vaccines in China. Image: iStock/Golden_Brown
Date: Jun 5, 2019
Duration: 20 Min
Already have an account?
Sponsored by Pullan Consulting
Image: iStock/Golden_Brown
This webcast features: Dr. Linda Pullan, Founder, Pullan Consulting
China’s biopharmaceutical industry is continuing its growth momentum. This robust growth is boosted by continuous investment into the sector. A clear strategic indicator of the government’s intentions in biopharma and biologics has been the China’s investment in biopharma industrial hubs, which will have added more than USD $300 billion to the biological industry nationwide by 2020. In Part 2 of our series, Dr. Linda Pullan, Principal, Pullan Consulting, covers China investments, as well as advice for negotiating China deals.
Watch the recorded webcast below.
About the Author
You May Also Like
Webinars
Sponsored Content
Jun 5 - Jun 6, 2024
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More
